

Press release - Regulated Information / Transparency Statement
27 April 2018

Thomas M. Clay – Transfer Landon T Clay 2016-1 Annuity Trust, Landon T Clay 2017-1 Annuity Trust to the Estate of Landon T. Clay

Leuven, Belgium, 27 April 2018 – Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 27 April 2018 from Thomas M. Clay and the entities controlled by him (*Landon T Clay 2016-1 Annuity Trust, Landon T Clay 2017-1 Annuity Trust, Estate of Landon T. Clay, East Hill Head Fund. LLC, Manadnock Charitable Lead Annuity Trust, Clay Fellowship Charitable Trust, The Clay Mathematics Institute, inc.*)

On 27 April, Thomas M. Clay reported that the completion of the transfer of the Landon T Clay 2016-1 Annuity Trust, Landon T Clay 2017-1 Annuity Trust into the Estate of Landon T. Clay

A result, the Estate of Landon T Clay, increased from 0% to 4,10%, crossing the 3% threshold.

On 27 April 2018, based on all received transparency declarations received, ThromboGenics NV is aware of a total participation by Thomas M Clay and entities controlled by him, of 3,361,555 shares or 8,78%.

For further information please contact:

<u>ThromboGenics</u> Wouter Piepers, Global Head of Corp Coms & Investor relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	<u>Citigate Dewe Rogerson</u> David Dible/ Sylvie Berrebi/ Isabelle Andrews Tel: +44 20 7638 9571 thrombogenics@citigatedewerogerson.com
---	--

About ThromboGenics

More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.